ADMA Biologics (NASDAQ: ADMA) reported Q2 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $60.13 million versus the consensus estimate of $55.5 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.